Company news
Tempest Therapeutics, Inc. (NASDAQ:TPST) news
Tempest Therapeutics, Inc. news releases on 6ix. Latest, Sep 23, 2026: Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Press releases & updates
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
September 23, 2026
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 21, 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 13, 2026
Tempest Reports Year End 2025 Financial Results and Provides Business Update
March 29, 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement
March 23, 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
March 10, 2026
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 24, 2026
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
February 11, 2026
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
February 4, 2026
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
January 20, 2026
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
November 26, 2025
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
November 25, 2025
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
November 19, 2025
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
August 13, 2025
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
June 30, 2025
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
June 11, 2025
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
June 5, 2025
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
April 28, 2025
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
April 21, 2025
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
April 9, 2025
Tempest Reports Year End 2024 Financial Results and Provides Business Update
March 27, 2025
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
March 13, 2025
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
February 9, 2025
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 6, 2025
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
January 5, 2025
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
November 11, 2024
Tempest Extends Limited Duration Stockholder Rights Plan
October 9, 2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
October 9, 2024
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
September 17, 2024
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
August 20, 2024
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
August 14, 2024
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
June 19, 2024
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
June 17, 2024